26/F, HKRI Centre One, HKRI Taikoo Hui
288 Shimen Road（No.1)
Shanghai 200041, P. R. China
T: (86-21) 5298-5488
F: (86-21) 5298-5492

20380 Town Center Lane, Suite 128
Cupertino, CA 95014, USA
T: +1 888 886 8168
F: +1 888 808 2168

April 7, 2025

Morgan Stanley Asia Limited ("Morgan Stanley")
46/F, International Commerce Centre
1 Austin Road West
Kowloon
Hong Kong

Jefferies Hong Kong Limited* ("Jefferies")
26/F, Two International Finance Centre
8 Finance Street, Central
Hong Kong

CITIC Securities (Hong Kong) Limited* ("CITICS")
18/F, One Pacific Place
88 Queensway
Hong Kong

(Morgan Stanley, Jefferies* and CITICS* are collectively referred to as the "**Joint Sponsors**")

CLSA Limited*
18/F, One Pacific Place
88 Queensway
Hong Kong

China International Capital Corporation Hong Kong Securities Limited ("CICC")
29/F, One International Finance Centre
1 Harbour View Street
Central

Hong Kong

(Morgan Stanley, Jefferies*, CLSA Limited* and CICC are collectively referred to as the "**Joint Representatives**" as defined in the Prospectus)

(* in no particular order)

(for themselves and on behalf of the Underwriters (as defined in the Prospectus)

Re: Duality Biotherapeutics, Inc.

Ladies and Gentlemen:

Duality Biotherapeutics, Inc., together with its subsidiaries (collectively, the "Company"), have requested us to conduct a due diligence review on certain intellectual property matters regarding the Company. We are providing this letter pursuant to the Hong Kong Underwriting Agreement and the International Underwriting Agreement (collectively, the "Underwriting Agreements") as defined in the prospectus ("Prospectus"), each in connection with the proposed initial public offering of the Company in the Hong Kong Stock Exchange (the "Offering"). We act as special patent counsel to the Company and our representation has been limited to matters individually referred to us by the Company.

In connection with this letter, we have reviewed the statements included in the Prospectus, the pricing disclosure package, the final offering circular and the prospectus supplement (if any) of the Company in relation to the Offering (the "Disclosure Documents") related to the patents and patent applications listed in Appendix A attached hereto (the "Company Patents") and the license agreements listed in Appendix B attached hereto (the "License Agreements"), which are made in the section titled "SUMMARY" under the heading of "INTELLECTUAL PROPERTY", section titled "RISK FACTORS" under the heading of "RISKS RELATING TO INTELLECTUAL PROPERTY RIGHTS", section titled "REGULATORY OVERVIEW" under the heading of "Patents", section titled "BUSINESS" under the headings of "INTELLECTUAL PROPERTY" and "Legal Proceedings Regarding Certain Patent Applications", section titled "Appendix IV STATUTORY AND GENERAL INFORMATION" under the headings of "2. Intellectual Property Rights (ii) Patents" (collectively, the "Patent Statements"). Except with respect to the Patent Statements, we did not participate in the preparation of the Disclosure Documents, and we have not been consulted to advise on any other part of the Disclosure Documents. We have limited our review of the Disclosure Documents to the Patent Statements.

The purpose of our professional engagement was not to establish or confirm factual matters set forth in the Prospectus, and we have not undertaken any obligation to verify those factual matters. Accordingly, except to the extent of our opinions set forth

in paragraphs A to N below, we are not passing upon and we assume no responsibility for the accuracy, completeness or fairness of the statements contained in or incorporated by reference into the Disclosure Documents.

Based on the foregoing and subject to the assumptions, qualifications, limitations and exceptions as stated in this letter, we advise you that:

A. Nothing has come to our attention causing us to believe that any of the Patent Statements contains any untrue statement of material fact or fails to state any material fact necessary to make the statements therein not misleading, and, to our knowledge, all such statements are accurate and complete and present fairly the information therein.

B. Appendix A contains a list of all material patents and patent applications owned by the Company. Except as described in the intellectual property due diligence report dated April 2, 2025, we have not become aware of any facts causing us to believe that the Company does not own or otherwise possess sufficient rights under all patent rights, including in-licensed patent rights, that are currently employed by the Company in connection with their respective businesses, or that is necessary for the manufacture, importation, use or sale of its product candidates as described in the Disclosure Documents. We have not become aware of any facts causing us to believe that the Company does not own or has not obtained licenses for, or other rights to use, Company Patents described as being owned or licensed or used by them as described in the Disclosure Documents.

C. Except as described in the intellectual property due diligence report, we have not become aware of any facts causing us to believe that the Company does not own or otherwise possess sufficient rights under the License Agreements for the manufacture, importation, use or sale of their product candidates as set forth in the License Agreements subject to terms, conditions and limitations set forth in the License Agreements.

D. We are not aware of any third-party issued patent rights that would be infringed by the manufacture, importation, use or sale by the Company of the Company's product candidates as described in the Disclosure Documents.

E. We are not aware of any third-party patent rights that, in our opinion, are valid and enforceable and are embodied by or are necessary for the purpose of the manufacture, importation, use or sale of the Group's drug candidates, as described in the Disclosure Documents.

F. To our knowledge, except for the patent ownership lawsuits between the Company and a third party and certain copyright infringement allegations as described in the intellectual property due diligence report and a separate patent litigation legal opinion, there is no claim, action, suit or proceeding pending or threatened against the Company alleging that the Company has infringed,

misappropriated or otherwise violated any intellectual property rights of any third party. We have not become aware of any facts causing us to believe that the current or planned development and commercialization of the Company's product candidates, as described in the Disclosure Documents, would infringe any issued patents of any third party (it being understood that the opinion in this paragraph E is made without giving effect to any exemption under U.S. patent law or analogous foreign law to which the Company may be entitled (e.g., 35 U.S.C. Section 271(e)(1)). To our knowledge, the Company has not in respect of any patent received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.

G. We have not become aware of any facts causing us to believe that the claims of the issued, unexpired patents included in the Company Patents are invalid or unenforceable under the laws of People's Republic of China (solely for the purposes of this opinion, excluding Hong Kong, the Macau Special Administrative Region and the islands of Taiwan) and the United States.

H. To our knowledge, no claim, action, suit or proceeding (including any interference, post grant reexamination, derivation, *inter partes* review, post grant review, opposition or other judicial or administrative proceeding) pertaining to the validity, enforceability or scope of any patents or other intellectual property rights owned by or exclusively licensed to the Company has been threatened or declared.

I. To our knowledge, there are no liens, encumbrances or security interests against any Company Patents for the benefit of a third party.

J. Based on the information provided to us by the Company and except as described in the intellectual property due diligence report, any inventors listed in the patents and patent applications owned by the Company in Appendix A, (a) were employees of the Company at the time of their invention or discovery of the subject matter of the inventions in such patents and patent applications, and (b) executed an agreement assigning to the Company such person's entire right, title and interest in and to any such inventions, including all intellectual property rights therein and thereto.

K. Based on information provided to us by the Company, we are not aware of any prior art references that may render any matters or subjects under the U.S. patent applications set forth in Appendix A unpatentable that has not been disclosed to the U.S. Patent and Trademark Office pursuant to the U.S. patent laws.

L. To our knowledge, all applicable fees, surcharges and administrative procedures in relation to the maintenance of patents or patent applications owned by the Company have been duly and properly paid and proceeded.

M. With respect to the material in-licensed agreements included in Appendix B, in terms of our knowledge under the laws of the People's Republic of China,

a. except as described in the intellectual property due diligence report, the licensor is the listed holder of the patent on the record of the public information of the patents in the People's Republic of China and the United States, or has obtained authorization from such listed holder of the patent for entering into such in-licensed agreements;

b. based on the Company's confirmation, each of the in-licensed agreements has been duly executed and delivered by the licensors and the Company;

c. each of the in-licensed agreements constitutes a valid and binding agreement of the Company and each other party thereto, enforceable against the Company and such other party;

d. each of the in-licensed agreements is in full force and effect; and

e. based on the Company's confirmation, none of the Company or the licensors is in default under the terms of any such in-licensed agreement, and no event or circumstance has occurred that, with notice or lapse of time or both, would constitute any event of default thereunder.

N. With respect to the material out-licensing agreements included in Appendix B, in terms of our knowledge under the laws of the People's Republic of China,

a. based on the Company's confirmation, each of the out-licensing agreements has been duly executed and delivered by the licensees and the Company;

b. each of the out-licensing agreements constitutes a valid and binding agreement of the Company and each other party thereto, enforceable against the Company and such other party;

c. each of the out-licensing agreements is in full force and effect; and

d. based on the Company's confirmation, none of the Company or the licensees is in default under the terms of any such out-licensing agreement, and no event or circumstance has occurred that, with notice or lapse of time or both, would constitute any event of default thereunder.

The opinions expressed herein are also subject to the following assumptions, limitations, qualifications and exceptions:

(a) As to matters of fact, we have assumed the authenticity and validity of all records furnished to us by the Company and the information and certificates from various public officials, and we have not made any independent investigation or verification of the authenticity and validity of such records, information and certificates.

(b) Whenever our opinions herein are qualified by the phrase "to our knowledge", or "known to us" or similar phrases, the relevant knowledge is limited to the current actual knowledge after due and careful inquiry of those attorneys presently in our firm who have performed substantive legal services for the Company in connection with this opinion.

(c) Except for the issuance of a separate intellectual property due diligence report on April 2, 2025, a separate patent litigation legal opinion on April 3, 2025, and our investigation in connection therewith, and except for our discussions with the Company and our review of documents provided by the Company in connection with this Offering, we have not made any independent investigation with respect to the legal status of the Company Patents, whether any of the Company Patents covers the Company's product candidates as described in the Disclosure Documents, whether the pending claims that cover the Company's relevant product candidates in the patent applications of the Company Patents are assured to be granted, and whether any third party intellectual property rights constitute a hindrance for the manufacture, importation, use or sale of the Company's product candidates as described in the Disclosure Documents.

(d) The opinions expressed herein represent our reasonable judgment as to the matter of law addressed herein, based upon the facts presented, and are not, and shall not be construed as, a guarantee.

(e) In acting as patent counsel to the Company, we have not been involved with the prosecution of the Company Patents. Any opinions set forth in this letter are limited to the patent laws of the People's Republic of China and the patent laws of the United States, to the extent that the same may apply to or govern such matters addressed herein.

(f) We have assumed each of the License Agreements has been duly authorized, executed and delivered by the other parties thereto, and we have not made any independent investigation or verification of such authenticity and validity of such records, information and certificates. We have also assumed that each of the License Agreements has been entered based on mutual assent, and the parties other than the Company have acted in good faith and dealt fairly, and there are no incidences of fraud, deceit, misrepresentation, duress, mistake, fraudulent inducement and unconscionability on the parties other than the Company.

(g) We have conducted certain freedom-to-operate searches for six drug candidates of the Company, *i.e.*, all the Core Products and Key Products as defined in the Disclosure Documents, in China and the U.S. While our searches for these six drug candidates were comprehensive based on the information available to us as of the Last Practicable Date, (i) we are not aware of any third-party issued patent rights that would be infringed by the

manufacture, importation, use or sale by the Company of these six specific drug candidates, and (ii) we have not conducted similar searches for the Company's other drug candidates. Based on the diligence response received from the Company and based on the representations made by the Company, we are not aware of any third-party issued patent rights that would be infringed by the manufacture, importation, use or sale by the Company of the Company's other drug candidates.

This letter is provided to you in your capacity as the Joint Sponsors, the Joint Global Coordinators and/or the Underwriters under the Underwriting Agreements and is solely for your benefit in connection with the Offering. This letter may not be relied upon by you for any other purpose. This letter may also not be provided to or relied upon by any other person or entity for any purpose, including, without limitation, any person or entity that acquires any securities of the Company from any of the Underwriters without our prior written consent, which we may withhold at our sole discretion. Notwithstanding these limitations, this letter can be disclosed (i) to Joint Sponsors, the Joint Global Coordinators and/or the Underwriters' affiliates and its (including its' affiliates) directors, officers, employees, legal, financial and other professional advisers (including the professional advisers engaged by the Company in its proposed initial public offering), regulators, (ii) for the purpose of responding to requests to review this letter by governmental, regulatory or judicial authorities having competent jurisdiction over you and (iii) in connection with the defense of any legal or regulatory proceeding or investigation arising out of the Offering, *provided* that JunHe LLP and Jun He Law Offices P.C. are given written notice in advance where practicable (to the extent permitted by applicable laws to do so).

This letter is limited to the matters expressly set forth herein, and no opinion has been implied, or may be inferred, beyond the matters expressly stated.

This letter is based on the law and facts as of the date hereof and we undertake no obligation or responsibility to update or supplement this letter to reflect any facts, circumstances, or changes in the law that may later occur or come to our attention.

(Signature Page to Follow)

(Signature Page of Project Diamond – IP Opinions)

Very truly yours,

君合律师事务所上海分所

JunHe LLP

Jun He Law Offices P.C.

Jun He Law Offices P.C.

APPENDIX A – MATERIAL PATENTS AND PATENT APPLICATIONS OWNED BY THE COMPANY

No.	Application No.	Publication No.	Country/ Region	Applicant/Assignee	Filing Date	Legal Status	Expiration Date[1]
1.	CN202180018263.3	CN115175705A	CN	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
2.	CN202211407530.9	CN115925796B	CN	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
3.	CN202211403184.7	CN116199739B	CN	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
4.	CN202310152789.1	CN116239601B	CN	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
5.	US17/825,090	US11685742B2	US	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
6.	US17/828,433	US11607459B1	US	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
7.	US18/147,070	US11952384B2	US	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
8.	US18/187,935	US20230331738A1	US	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
9.	US18/495,455	US12091418B2	US	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
10.	US18/506,610	US12168667B2	US	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
11.	EP21874533.9	EP4223318A1	EP	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A

[1] For the granted patents in jurisdictions other than China and U.S., the expiration date is assumed to be the 20th anniversary from the filing date, and no patent term extension is considered.

12.	EP24204055.8	EP4516357A2	EP	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
13.	TW110136259	TW202214230A	TW	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
14.	HK42023073881.7[2]	HK40085633B	HK	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
15.	HK42023077283.2[3]	HK40088305B	HK	映恩生物制药(苏州)有限公司	2021-09-29	Granted	2041-09-29
16.	HK62023080157.8[4]	HK40092723A	HK	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
17.	AU2021354823	AU2021354823A1	AU	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
18.	BR1120230058465	BR112023005846A2	BR	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
19.	CA3195515A1	CA3195515A1	CA	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
20.	IL301793	IL301793A	IL	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
21.	IN202317025980	IN202317025980A	IN	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
22.	JP2023-520181	JP2023551355A	JP	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
23.	KR10-2023-7011470	KR1020230079085A	KR	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A

[2] Based on CN202211407530.9

[3] Based on CN202211403184.7

[4] Based on EP21874533.9

24.	MX/a/2023/003778	MX2023003778A	MX	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
25.	NZ798378	NZ798378A	NZ	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
26.	SG11202302490W	SG11202302490WA	SG	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
27.	ZA2023/04874	ZA202304874A	ZA	映恩生物制药(苏州)有限公司	2021-09-29	Pending	N/A
28.	TW111132293	TW202327619	TW	映恩生物制药（苏州）有限公司	2022-08-26	Pending	N/A
29.	CN202280041892.2	CN117500816B	CN	映恩生物制药（苏州）有限公司	2022-08-25	Granted	2042-08-25
30.	US18/686,076	US20250002527A1	US	映恩生物制药（苏州）有限公司	2022-08-25	Pending	N/A
31.	EP22860594.5	EP4393937A1	EP	映恩生物制药（苏州）有限公司	2022-08-25	Pending	N/A
32.	JP2024513065	JP2024531480A	JP	映恩生物制药（苏州）有限公司	2022-08-25	Pending	N/A
33.	TW112102804	TW202341984A	TW	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
34.	CN202380013747.8	CN118434453A	CN	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
35.	EP23746246.0	EP4470570A1	EP	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
36.	AU2023213783	AU2023213783A1	AU	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
37.	BR1120240152251	BR112024015225A2	BR	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A

38.	HK62024099693[5]	HK40111932A	HK	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
39.	IL314567	IL314567A	IL	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
40.	IN202427059198	IN202427059198A	IN	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
41.	JP2024544709	JP2025503214A	JP	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
42.	KR10-2024-7027679	KR1020240157659A	KR	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
43.	MX/a/2024/009159	MX2024009159A	MX	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
44.	NZ813241	NZ813241A	NZ	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
45.	SG11202405179T	SG11202405179TA	SG	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
46.	ZA2024/05877	ZA202405877A	ZA	映恩生物制药(苏州)有限公司	2023-01-19	Pending	N/A
47.	TW112121031	TW202400248A	TW	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
48.	US18/511,591	US12138316B2	US	映恩生物制药（苏州）有限公司	2023-06-06	Granted	2043-06-06
49.	CN202380033800.0	CN119384296A	CN	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
50.	AU2023282410	AU2023282410A1	AU	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
51.	IL317340	IL317340A	IL	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A

[5] Based on CN202380013747.8

52.	IN202417091186	IN202417091186A	IN	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
53.	KR1020247040682	KR1020250021316A	KR	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
54.	MX2024015163	MX2024015163A	MX	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
55.	SG11202408543S	SG11202408543SA	SG	映恩生物制药（苏州）有限公司	2023-06-06	Pending	N/A
56.	PCT/CN2023/142481	WO2024140846A1	PCT	映恩生物科技（上海）有限公司	2023-12-27	Pending	N/A
57.	TW112151152	TW202430224A	TW	映恩生物科技（上海）有限公司	2023-12-27	Pending	N/A
58.	TW112119159	TW202400652A	TW	映恩生物制药（苏州）有限公司	2023-05-23	Pending	N/A
59.	HK62025103092.5[6]	HK40115076A	HK	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
60.	CN202380042253.2	CN119365488A	CN	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
61.	AU2023274754	AU2023274754A1	AU	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
62.	IL317248	IL317248A	IL	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
63.	IN202427094765	IN202427094765A	IN	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
64.	KR10-2024-7042394	KR20250017233A	KR	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
65.	MXa2024014591	MX2024014591A	MX	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A

[6] Based on CN202380042253.2

66.	NZ816516	NZ816516A	NZ	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
67.	SG11202408208Q	SG11202408208QA	SG	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
68.	ZA202409164	ZA202409164A	ZA	映恩生物制药（苏州）有限公司	2023-05-24	Pending	N/A
69.	PCT/CN2023/142457	WO2024140838A1	PCT	映恩生物制药（苏州）有限公司	2023-12-27	Pending	N/A
70.	TW112151089	TW202432188A	TW	映恩生物制药（苏州）有限公司	2023-12-27	Pending	N/A

APPENDIX B – LICENSE AGREEMENTS

1. A License Agreement between Duality Bio HK Limited and WuXi Biologics Ireland Limited executed in 2022, an Amended and Restated License Agreement between Duality Bio HK Limited and WuXi Biologics Ireland Limited dated March 31, 2023, and an Assignment and Assumption Agreement between Duality Bio HK Limited and Duality Biologics (Suzhou) Co. Ltd. dated March 31, 2023;

2. A Technology License and Collaboration Agreement dated November 29, 2021 and a Supplementary Agreement to the Technology License and Collaboration Agreement dated March 18, 2024 between Duality Biologics (Suzhou) Co., Ltd. and Beijing Sinotau Pharmaceutical Inc., a Technology License and Collaboration Agreement between Duality Biologics (Suzhou) Co., Ltd. and Beijing Sinotau Pharmaceutical Inc. dated March 18, 2024, and an Intellectual Property License Agreement between Beijing Sinotau Pharmaceutical Inc. and Beijing Sinotau Biotechnology Co., Ltd. dated November 1, 2021;

3. A B7H4 Antibody License Agreement between Duality Biologics (Suzhou) Co., Ltd. and Harbour BioMed (Suzhou) Co., Ltd. (current name Nona Biosciences (Suzhou) Co., Ltd.) dated January 18, 2022, and a B7H4 Antibody License Agreement between Duality Biologics (Suzhou) Co., Ltd. and Nona Biosciences (Suzhou) Co., Ltd. dated October 31, 2023;

4. A Technology License and Collaboration Agreement between Duality Biologics (Suzhou) Co., Ltd., and Dashi Pharmaceutical (Guangdong) Co., Ltd., Shenzhen Chuangshi Biologics Co., Ltd., and Shanghai Maishi Biotechnology Co., Ltd. dated October 9, 2022 and a Supplementary Agreement to the Technology License and Collaboration Agreement executed between Dashi Pharmaceutical (Guangdong) Co., Ltd. and Duality Biologics (Suzhou) Co., Ltd. dated May 15, 2023;

5. An Amended and Restated Strategic Collaboration Agreement between Duality Biologics (Suzhou) Co., Ltd. and Shanghai Haoyuan Chemexpress Co., Ltd. dated March 31, 2023;

6. A Cell Line License Agreement between DualityBio HK Limited and WuXi Biologics (Hong Kong) Limited dated June 21, 2021, a Deed of Amendment to Cell Line License Agreement between DualityBio HK Limited and WuXi Biologics (Hong Kong) Limited, and a Deed of Assignment and Assumption between DualityBio HK Limited and Duality Biologics (Suzhou) Co., Ltd. dated March 31, 2023;

7. A License and Collaboration Agreement between Duality Biologics (Suzhou) Co., Ltd. and BioNTech SE dated March 16, 2023;

8. A License and Collaboration Agreement (Trop2) between Duality Biologics (Suzhou) Co., Ltd. and BioNTech SE dated August 4, 2023;

9. A License and Collaboration Agreement between Duality Biologics (Suzhou) Co., Ltd. and BioNTech SE dated March 31, 2023;

10. An Exclusive License Agreement between Duality Biologics (Suzhou) Co., Ltd. and Adcendo ApS dated December 23, 2022, an Amendment No.1 to Exclusive License Agreement dated February 22, 2023;

11. An Exclusive Option, License and Collaboration Agreement between Duality Biologics (Suzhou) Co. Ltd. and BeiGene, Ltd., dated July 9, 2023;

12. A Commercialization Collaboration Agreement between Duality Biotechnology (Shanghai) Co., Ltd. and Shenyang Sunshine Pharmaceutical Co., Ltd. and Liaoning Sunshine Bio-Pharmaceutical Co., Ltd., dated January 10, 2025 and effective as of December 31, 2024.